Innophore GmbH

Identifying the right drug among millions of possible molecular combinations is one of the most expensive and time-consuming challenges in modern medicine. Pharmaceutical labs spend years and billions of euros searching for promising candidates, most of which never make it through clinical trials. Innophore attacks this problem at its core, offering a computational platform for protein and drug discovery that dramatically accelerates the earliest stages of research. The approach draws on computational biology and structural bioinformatics: rather than proceeding through trial and error in the lab, Innophore uses advanced computational models to simulate and predict interactions between proteins and candidate molecules. This allows researchers to narrow the field far more efficiently, identifying enzymes, pharmaceutical candidates, and drug repurposing opportunities — applying existing drugs to new therapeutic indications — before any physical experimentation begins. The target market includes biotech and pharma companies, as well as R&D teams at large pharmaceutical groups and academic institutions that need computational tools to validate hypotheses before investing lab resources. This is a fast-growing market, driven by the explosion of genomic and proteomic data and the growing adoption of artificial intelligence in life sciences. Innophore's business model is B2B, centered on customized services and solutions. The company does not sell off-the-shelf software — it works closely with specific clients to answer precise scientific questions: which enzyme catalyzes a given reaction? Which molecule is most likely to bind to this therapeutic target? Questions that, with traditional methods, can take years of experimentation, and that a computational approach can answer in a fraction of the time.